PRIMAXIN IM 500

Compare PRIMAXIN IM 500  to:
Compare
Compare

Generic Name for PRIMAXIN IM 500

Imipenem 500mg, cilastatin sodium 500mg; IM inj; sodium content 2.8mEq/g imipenem.

Legal Classification:

Rx

Pharmacological Class for PRIMAXIN IM 500

Carbapenem (thienamycin) + dehydropeptidase I inhibitor.

Manufacturer of PRIMAXIN IM 500

Merck & Co., Inc.

Indications for PRIMAXIN IM 500

Susceptible mild to moderate infections including lower respiratory tract, intraabdominal, skin and skin structure, gynecologic. IM form not for severe or life-threatening infections.

Adult dose for PRIMAXIN IM 500

Base dose on imipenem component. Lower respiratory tract, skin and skin structure, gynecologic: mild to moderate: 500–750mg every 12 hours. Intraabdominal: 750mg every 12 hours. CrCl <20mL/min: not recommended.

Children's dosing for PRIMAXIN IM 500

Not recommended.

Also:

Contraindications for PRIMAXIN IM 500

IM: Allergy to amide-type local anesthetics. Heart block. Severe shock.

Precautions for PRIMAXIN IM 500

Penicillin, cephalosporin, or other allergy. CNS disorders (esp. brain lesions or seizures). Renal impairment: reduce dose. Hemodialysis: see literature. GI disease (esp. colitis). IM: prepare with lidocaine (see literature). Pregnancy (Cat.C). Nursing mothers.

Interactions for PRIMAXIN IM 500

Concomitant ganciclovir (increased seizure risk), probenecid: not recommended. May antagonize valproic acid; monitor (consider alternative therapy).

Adverse Reactions for PRIMAXIN IM 500

Local reactions, GI upset, confusion, myoclonia, seizures, changes in serum electrolytes, dizziness, somnolence, anaphylaxis, blood dyscrasias, elevated liver enzymes, fever, rash, hypotension.

How is PRIMAXIN IM 500 supplied?

Vials (IV)—25
Vials (IM)—10

Related Disease:

Infections, bacterial~systemic antiinfectives

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.